GREENWICH LIFESCIENCES, INC. Increase (Decrease) in Accounts Payable
GREENWICH LIFESCIENCES, INC. (GLSI) reported Increase (Decrease) in Accounts Payable of $154.01 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $519.47K.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$365.46K.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $2.14M, a 5.52% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $602.63K.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in accounts payable for fiscal 2025 was $2.07M, a 18.66% decline from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in accounts payable for fiscal 2024 was $2.55M, a 7079.27% increase from fiscal 2023.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in accounts payable for fiscal 2023 was $35.47K.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in accounts payable for fiscal 2021 was -$526.73K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $519.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $154.01K 10-Q · filed 2026-08-11 | $2.29M derived: sum of 3 quarters · filed 2026-08-11 | $2.90M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | -$365.46K 10-Q · filed 2026-06-04 | $1.77M derived: sum of 2 quarters · filed 2026-06-04 | $2.38M derived: sum of 3 quarters · filed 2026-06-04 | $2.35M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $2.74M derived: sum of 2 quarters · filed 2026-06-01 | $2.71M derived: sum of 3 quarters · filed 2026-08-11 | $2.07M 10-K · filed 2026-06-01 | |||
| 2025-09-30 | $602.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $574.59K derived: sum of 2 quarters · filed 2026-08-11 | -$68.65K 10-Q · filed 2025-11-14 | $1.96M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | -$28.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$671.28K 10-Q · filed 2026-08-11 | $118.94K 10-Q · filed 2025-08-14 | $1.36M derived: sum of 3 quarters · filed 2026-08-11 | $796.43K derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$643.24K 10-Q · filed 2026-06-04 | -$129.66K 10-Q · filed 2025-05-20 | $1.38M derived: sum of 2 quarters · filed 2026-06-04 | $824.48K derived: sum of 3 quarters · filed 2026-06-04 | $1.81M derived: sum of 4 quarters · filed 2026-06-04 | ||
| 2024-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.47M derived: sum of 2 quarters · filed 2026-06-01 | $2.46M derived: sum of 3 quarters · filed 2026-06-01 | $2.55M 10-K · filed 2026-06-01 | $921.22K 10-K · filed 2025-04-15 | ||
| 2024-09-30 | -$560.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $428.18K derived: sum of 2 quarters · filed 2025-11-14 | $518.44K 10-Q · filed 2025-11-14 | $543.86K derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $988.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.08M 10-Q · filed 2025-08-14 | $1.10M derived: sum of 3 quarters · filed 2025-08-14 | $1.03M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $90.27K 10-Q · filed 2025-05-20 | $115.68K derived: sum of 2 quarters · filed 2025-05-20 | $46.12K derived: sum of 3 quarters · filed 2025-05-20 | ||||
| 2023-12-31 | $25.41K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$44.15K derived: sum of 2 quarters · filed 2025-04-15 | $35.47K 10-K · filed 2025-04-15 | ||||
| 2023-09-30 | -$69.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $10.06K 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $79.62K 10-Q · filed 2024-08-14 | ||||||
| 2021-12-31 | -$75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$406.73K derived: sum of 2 quarters · filed 2023-03-31 | -$406.73K derived: sum of 3 quarters · filed 2023-03-31 | -$526.73K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$331.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$331.73K derived: sum of 2 quarters · filed 2022-11-14 | -$451.73K 10-Q · filed 2022-11-14 | -$559.28K derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$120.00K 10-Q · filed 2022-08-15 | -$227.55K derived: sum of 3 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | -$120.00K 10-Q · filed 2022-05-20 | -$227.55K derived: sum of 2 quarters · filed 2022-05-20 | |||||
| 2020-12-31 | -$107.55K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$92.55K 10-K · filed 2022-03-21 | |||||
| 2020-09-30 | $15.00K 10-Q · filed 2021-11-15 | ||||||
| 2019-12-31 | $70.31K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $393.40K 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | $323.09K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |